invivodata, inc., the industry leader in patient reported outcomes (PRO) solutions and consulting services for global clinical research, announced that it has secured an undisclosed amount of financing from MMV Financial ("MMV").

invivodata has led the industry in developing innovative patient- and site-based electronic PRO solutions that enable researchers to overcome the limitations of paper-based diaries and capture real-time data that meets FDA guidance regarding the reliability of PRO data in clinical trials. invivodata is privately held with investment from River Cities Capital Funds, Peninsula Equity Partners, Hawthorne Partners, Glynn Capital Management, Stanford University, The Entrepreneurs' Funds, Novus Ventures, Horizon Ventures and Resource Ventures.

"invivodata will use this financing to bolster our sales and marketing efforts to support our continued growth and to address new opportunities," said Doug Engfer, CEO, invivodata. "We are extremely pleased with MMV's flexibility in structuring a deal that suited us and their commitment to a deadline. We look forward to our new relationship with MMV."

"invivodata has exhibited a strong growth in its scientific and regulatory consulting business and expanded its partnerships with the world's top Contract Research Organizations" said Ron Patterson, executive vice president, MMV Financial. "We believe that the Company is well positioned to extend its leadership in the ePRO market and continue delivering consistent results to new and existing customers. We have high confidence in the Company leadership and are excited to be a part of their ongoing success."

Back to the e-newsletter